Janssen Signs a Multiple Agreement with Dyadic to Manufacture Therapeutic Protein Candidates Using C1 Platform
Shots:
- Dyadic to receive $500,000 up front for non-exclusive rights, ~$1.80M in R&D funding to develop C1 production cell lines for its therapeutic protein candidates against multiple biologic targets. If exercise its option, Dyadic is eligible to receive commercial, development & regulatory milestones
- Janssen gets an option to pay a mid-seven figure fee for an exclusive license to use the C1 platform for the manufacturing of therapeutic proteins directed to one specific target & also gets the rights to add additional non-exclusive targets to the collaboration
- Additionally, Janssen will develop C1 cell lines against licensed targets upon completion of C1 platform technology transfer
Ref: Globe Newswire | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
